Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.

c-Met binds to and phosphorylates PARP1 in cancer cells, thereby reducing PARP1 binding to a PARP inhibitor; c-Met and PARP inhibitor combination therapy shows improved efficacy in preclinical models of breast and lung cancer.